Search
Vanda Pharmaceuticals Inc
VNDAAdd to Watchlist
5.100USD
-0.080-1.54%
Close 07-31 16:00（ET）Quotes delayed by 15 min
306.69MMarket Cap
LossP/E TTM
More Details of Vanda Pharmaceuticals Inc Company
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Vanda Pharmaceuticals Inc Info
Ticker SymbolVNDA
Company nameVanda Pharmaceuticals Inc
IPO dateApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Number of employees368
Security typeOrdinary Share
Fiscal year-endApr 12
AddressSuite 300E
CityWASHINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20037
Phone12027343400
Websitehttps://www.vandapharma.com/
Ticker SymbolVNDA
IPO dateApr 12, 2006
CEOPolymeropoulos (Mihael Hristos)
Company Executives of Vanda Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.59M
-70.28%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
219.05K
+18.99%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
204.77K
-141.34%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
160.67K
+25.89%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
128.47K
+32.38%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
122.59K
-236.09%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
112.85K
+36.86%
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.59M
-70.28%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
219.05K
+18.99%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
204.77K
-141.34%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
160.67K
+25.89%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
128.47K
+32.38%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
122.59K
-236.09%
FAQs
Who are the top five shareholders of Vanda Pharmaceuticals Inc?
The top five shareholders of Vanda Pharmaceuticals Inc are: Dr. Mihael Hristos Polymeropoulos, M.D.
How many institutions hold shares of Vanda Pharmaceuticals Inc (VNDA)?
As of 2026Q1, 353 institutions hold shares of Vanda Pharmaceuticals Inc, with a combined market value of approximately 47.15M, accounting for 78.40% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5252737.00.
What is the biggest source of revenue for Vanda Pharmaceuticals Inc?
In 2026Q1, the Fanapt business generated the highest revenue for Vanda Pharmaceuticals Inc, amounting to 117.30M and accounting for 54.28% of total revenue.